Abstract
Background
To prepare for a Japanese nationwide group study of patients with rhabdomyosarcoma (RMS), we examined the characteristics and outcomes of RMS patients treated recently in Japan.
Methods
We classified 331 RMS patients treated between 1991 and 2002 at 63 institutions according to the Intergroup Rhabdomyosarcoma Study V (IRS-V) risk-group classification.
Results
Ten-year survival rates were 86.3% for patients in low-risk subgroup A, 80.7% for low-risk subgroup B, 62.7% for intermediate-risk subgroup A, 61.7% for intermediate-risk subgroup B, and 38.1% for the high-risk group. The outcomes of the patients in the former three groups were 8%, 12%, and 21% worse than the outcomes of the respective patients in the IRS-III and early IRS-IV data. The frequency of the alveolar histological subtype was 21.8%. Chimera genes, which are useful markers for the alveolar subtype, had been examined in only 10% of the patients treated in the period of this investigation. The survival rates of our patients with embryonal and alveolar histological subtypes (65.9% and 63.4%, respectively) were not significantly different. Among the patients in the high-risk group, the 5-year survival of patients who received high-dose chemotherapy (HDC; 58.2%) was significantly better than that of patients who did not receive HDC (18.4%).
Conclusion
Patients in the lower-risk groups with embryonal-type tumors had poorer outcomes in this retrospective study. The better outcome of patients in the high-risk group is apparently due to the outstanding results obtained with an HDC regimen in a single institution. These results suggest that there is a need for: (1) a standard therapy, (2) a rapid central pathology review including a chimera gene analysis for the lower-risk group, and (3) evaluation of the efficacy of the high-dose regimen for the high-risk group in Japan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
WM Crist EA Gehan AH Ragab et al. (1997) ArticleTitleThe Third Intergroup Rhabdomyosarcoma Study J Clin Oncol 13 610–630
WM Crist JR Anderson JL Meza et al. (2001) ArticleTitleIntergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease J Clin Oncol 19 3091–3102 Occurrence Handle11408506 Occurrence Handle1:STN:280:DC%2BD3MzksFGhtQ%3D%3D
InstitutionalAuthorNameCommittee on Tumor Registration, Japanese Society of Pediatric Surgeons (1999) ArticleTitleThe clinical features and prognosis of rhabdomyosarcoma: follow-up studies on pediatric tumors from the Japanese Pediatric Tumor Registry 1981–1990 J Jpn Soc Pediatr Surg 35 716–738
Sugimoto T (2002) Rhabdomyosarcoma. A report for Grant-in-Aid (13–19) in Cancer Research, Ministry of Health, Labour and Welfare of Japan:467–468
T Sawada T Shikata T Matsumura et al. (1994) ArticleTitleAnalysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. NB Screening Study Group Prog Clin Biol Res 385 371–375 Occurrence Handle7972233 Occurrence Handle1:STN:280:ByqD283ksVE%3D
W Lawrence SuffixJr JR Anderson EA Gehan HM Maurer (1997) ArticleTitlePretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group Cancer 80 1165–1170 Occurrence Handle9305719 Occurrence Handle10.1002/(SICI)1097-0142(19970915)80:6<1165::AID-CNCR21>3.0.CO;2-5
W Laurence SuffixJr EA Gehan DM Hays et al. (1987) ArticleTitlePrognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II) J Clin Oncol 5 46–54
PH Sorensen JC Lynch SJ Qualman et al. (2002) ArticleTitlePAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group J Clin Oncol 20 2672–2679 Occurrence Handle12039929 Occurrence Handle10.1200/JCO.2002.03.137 Occurrence Handle1:CAS:528:DC%2BD38XkvF2mtr0%3D
RB Raney JR Anderson FG Barr et al. (2001) ArticleTitleRhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V J Pediatr Hematol Oncol 23 215–220 Occurrence Handle11846299 Occurrence Handle10.1097/00043426-200105000-00008 Occurrence Handle1:STN:280:DC%2BD387hsVentw%3D%3D
J Breneman J Anderson S Donaldson et al. (2001) ArticleTitlePrognostic factors and outcome in children with metastatic rhabdomyosarcoma – a report from the Intergroup Rhabdomyosarcoma Study IV Int J Radiat Oncol Biol Phys 51 A–210 Occurrence Handle10.1016/S0360-3016(01)02039-9
H Matsubara A Makimoto T Higa et al. (2003) ArticleTitlePossible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy Pediatr Hematol Oncol 20 201–210 Occurrence Handle12637216 Occurrence Handle1:CAS:528:DC%2BD3sXitVCmt70%3D
J Hara Y Osugi H Ohta et al. (1998) ArticleTitleDouble-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors Bone Marrow Transplant 22 7–12 Occurrence Handle9678789 Occurrence Handle10.1038/sj.bmt.1701283 Occurrence Handle1:STN:280:DyaK1czktF2huw%3D%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hosoi, H., Teramukai, S., Matsumoto, Y. et al. A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol 12, 137–145 (2007). https://doi.org/10.1007/s10147-006-0638-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-006-0638-6